Analysts' Actions: ARIA, EA, HGSI, BBBY

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Ariad Pharmaceutical ( ARIA) was initiated with a Buy rating at UBS. $20 price target. Near-term driver of phase I/II date from AP26113, UBS said.

Bed Bath & Beyond ( BBBY) was downgraded at Canaccord Genuity from Buy to Hold. $73 price target. Company is losing market share, Canaccord said.

Bill Barrett ( BBG) was initiated with a Hold rating at Deutsche Bank. $30 price target. Company remains highly leveraged to natural gas, Deutsche said.

BioMarin ( BMRN) was initiated with a Buy rating at UBS. $43 price target. GALNS can be a $500 million product, UBS said.

Electronic Arts ( EA) was initiated with a Neutral rating at Ascendiant. $16 price target. Concerns remain around industry growth and the company's key games, Ascendiant said.

Human Genome ( HGSI) was initiated with a Neutral rating at UBS. $8 price target. Company will continue to trade on monthly IMS sales for Benlysta, UBS said.

IDT Corp. ( IDT) was upgraded to hold at TheStreet Ratings.

MAP Pharmaceuticals ( MAPP) was downgraded to sell at TheStreet Ratings.

MercadoLibre ( MELI) was initiated with a Neutral rating at Goldman Sachs. Valuation call, based on a $93 price target, Goldman said.

Mattress Firm ( MFRM) was initiated with a Hold rating at Stifel Nicolaus. Valuation call, as the stock is up 132% since its IPO.

Packaging Corp. ( PKG) was upgraded at JP Morgan from Underweight to Neutral. Company continues to execute well.

AT&T ( T) was upgraded at JP Morgan to Overweight from Neutral. $33 price target. Higher tablet demand should drive ARPU growth, JP Morgan said.

United Therapeutics ( UTHR) was downgraded at Leerink Swann to Market Perform. Company is facing increased generic risk, Leerink Swann said.

Whiting Petroleum ( WLL) was initiated with a Buy rating at Brean Murray. $70 price target. Company was also placed on the Focus List. Company should deliver more consistent drilling results, Brean Murray said.

Stock Comments / EPS Changes

Apple ( AAPL) estimates, target were increased at Credit Suisse. Estimates were raised through 2013. Company is seeing higher iPhone sales, Credit Suisse said. Outperform rating and new $750 price target.

ADTRAN ( ADTN) price target was raised to $34 at Jefferies. Solid first-quarter results, Jefferies said. Hold rating.

American Express ( AXP) price target was raised at Guggenheim to $67. Digital platform should drive future growth, Guggenheim said. Buy rating.

Cree ( CREE) estimates, target were raised at Keybanc. Shares are now seen reaching $37. Estimates were also increased, as the industry cycle appears to be bottoming, Keybanc said. Buy rating.

If you liked this article you might like

After Soaring to $150, Can Incyte Stir Up More Upside?

Biotech Buoyed by Deal Talk

The Next Target in Biotech Land

The Next Target in Biotech Land

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)